08048035996
Spnib 50mg Good Quality Tablet to UK - London | Phoenix Exim | Trusted Exporter

1. General Information

Spnib 50 mg Tablet contains Dasatinib 50 mg, a prescription medicine belonging to the class of tyrosine kinase inhibitors (TKIs). It is an anti-cancer medicine primarily used for certain types of leukemia, particularly Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) and Ph+ acute lymphoblastic leukemia (ALL).

Spnib 50 mg is intended to be used under the supervision of a qualified oncologist or hematologist. It is not a medicine for self-treatment.

2. Product Information

  • Brand: Spnib 50
  • Active ingredient: Dasatinib
  • Strength: 50 mg
  • Dosage form: Tablet
  • Therapeutic class: Tyrosine kinase inhibitor / anti-cancer medicine
  • Primary therapeutic area: Hematological cancers
  • Manufacturer/Marketer: Zydus Healthcare
  • Prescription status: Prescription medicine
  • Typical pack information: 60 tablets, depending on the marketed pack

Product references confirm Spnib 50 mg contains dasatinib 50 mg.

3. Uses of Spnib 50 mg Tablet

Spnib 50 mg Tablet is used in the management of specific leukemia conditions, including:

  • Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML)
  • Certain phases of CML where previous treatment has not worked adequately or has not been tolerated
  • Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in appropriate patients

The exact indication and treatment regimen depend on the patient's diagnosis, disease phase, previous treatment and clinical response.

4. Benefits of Spnib 50 mg Tablet

Spnib 50 mg provides targeted anti-cancer activity. Dasatinib inhibits abnormal kinase signaling involved in the growth and survival of certain leukemia cells.

Potential therapeutic benefits include:

  • Helps inhibit abnormal cancer-cell growth
  • Helps control Philadelphia chromosome-positive leukemia
  • Provides targeted treatment against BCR-ABL-related signaling
  • May help slow disease progression in appropriate patients
  • Can be used when selected patients require an alternative or subsequent TKI treatment

The expected benefit varies according to the patient's disease characteristics and response to treatment.

5. Side Effects of Spnib 50 mg Tablet

Like other anti-cancer medicines, Spnib 50 mg can cause side effects. Possible adverse effects include:

  • Fluid retention
  • Pleural effusion
  • Fatigue
  • Headache
  • Nausea
  • Vomiting
  • Diarrhea
  • Abdominal pain
  • Muscle or joint pain
  • Skin rash
  • Reduced blood-cell counts
  • Bleeding or hemorrhage
  • Infection
  • Edema

Some reactions can be serious and require prompt medical attention.

6. Common Side Effects

Reported side effects include:

  • Headache
  • Fatigue
  • Nausea
  • Vomiting
  • Diarrhea
  • Abdominal discomfort
  • Muscle pain
  • Joint pain
  • Skin rash
  • Swelling or fluid retention
  • Low platelet count
  • Low neutrophil count
  • Anemia

Pleural effusion, pulmonary complications, significant bleeding and cardiac complications can occur and should be evaluated urgently if symptoms develop.

7. How to Use Spnib 50 mg Tablet

Spnib 50 mg should be taken only according to the dosage and schedule prescribed by the treating doctor.

General administration information:

  • Take the tablet by mouth with water.
  • It may generally be taken with or without food.
  • Swallow the tablet whole.
  • Do not crush, chew or break it unless specifically instructed by a healthcare professional.
  • Try to take it at the same time each day.
  • Do not change the dose or stop treatment without consulting the prescribing doctor.

The appropriate dose is individualized according to the leukemia type, treatment history, age and clinical circumstances.

8. How Spnib 50 mg Works

Spnib 50 mg contains dasatinib, which is a tyrosine kinase inhibitor.

Dasatinib blocks abnormal kinase proteins, including BCR-ABL, that can send signals promoting the growth and multiplication of leukemia cells. By inhibiting these signals, dasatinib can reduce the growth and survival of susceptible cancer cells.

9. Safety Advice for Spnib 50 mg

Spnib 50 mg is a potent prescription anti-cancer medicine and should be used under specialist supervision.

Pregnancy: Dasatinib can cause fetal harm. Patients who are pregnant, planning pregnancy or who could become pregnant should discuss appropriate precautions with their doctor.

Breastfeeding: Breastfeeding is generally not recommended during dasatinib treatment; discuss this with the treating physician.

Blood counts: Dasatinib can cause myelosuppression, including reduced platelets, neutrophils and red blood cells. Regular blood tests may therefore be required.

Heart and lung problems: Contact a doctor promptly for chest pain, breathing difficulty, persistent cough, palpitations or significant swelling because serious pulmonary or cardiovascular complications can occur.

Bleeding: Report unusual bruising, bleeding, black stools or other signs of significant bleeding.

Liver and kidney conditions: Inform the doctor about existing liver or kidney problems before treatment.

Drug interactions: Tell the doctor or pharmacist about all prescription medicines, over-the-counter medicines and supplements being used before starting dasatinib.

Storage: Follow the storage conditions printed on the product packaging and keep the medicine away from children.

10. Frequently Asked Questions (FAQs)

What is Spnib 50 mg Tablet?

Spnib 50 mg is a prescription anti-cancer tablet containing dasatinib 50 mg. It is used for certain Philadelphia chromosome-positive leukemia conditions.

What is the active ingredient in Spnib 50?

The active ingredient is dasatinib 50 mg.

What is Spnib 50 used for?

It is used primarily for certain forms of Ph+ chronic myeloid leukemia (CML) and Ph+ acute lymphoblastic leukemia (ALL).

Can Spnib 50 be taken without a prescription?

No. Spnib 50 is a prescription anti-cancer medicine and should be used only under appropriate medical supervision.

Can Spnib 50 cause breathing problems?

Yes. Dasatinib can cause pleural effusion and other pulmonary complications. New or worsening shortness of breath, chest discomfort or persistent cough should be medically evaluated promptly.

Can Spnib 50 be stopped suddenly?

Treatment should not be stopped or changed without discussing it with the treating oncologist.

Is Spnib 50 suitable for every leukemia patient?

No. Dasatinib is indicated for particular leukemia types and molecular characteristics. The treating specialist determines whether it is appropriate.

11. Substitutes for Spnib 50 mg

Because Spnib 50 contains dasatinib 50 mg, potential branded/generic alternatives may include other dasatinib 50 mg products.

Examples identified in Indian medicine references include:

  • Dasanat 50 mg
  • Dasania 50 mg
  • Dyronib 50 mg
  • Dasatib 50 mg
  • Dasather 50 mg

These products should not be considered automatically interchangeable without confirmation from the treating physician or pharmacist. The correct substitute must match the active ingredient, strength, dosage form and clinical indication.

12. SEO Keywords for Spnib 50 mg Tablet

High-Intent Product Keywords

  • Spnib 50 mg Tablet exporter from India
  • Spnib 50 mg Tablet supplier from Nagpur India
  • Spnib 50 mg Dasatinib 50 mg exporter
  • Spnib 50 mg Tablet pharmaceutical exporter
  • Spnib 50 mg Tablet wholesale supplier India
  • Dasatinib 50 mg Tablet exporter India
  • Dasatinib 50 mg pharmaceutical supplier
  • Spnib 50 mg Tablet international supplier
  • Spnib 50 mg anti cancer medicine supplier
  • Spnib 50 mg leukemia medicine exporter

International B2B SEO Keywords

  • Spnib 50 mg Tablet exporter to USA
  • Spnib 50 mg Tablet supplier to UK
  • Spnib 50 mg Tablet exporter to Australia
  • Spnib 50 mg Tablet supplier to Canada
  • Spnib 50 mg Tablet exporter to Singapore
  • Spnib 50 mg Tablet supplier to South Korea
  • Spnib 50 mg Tablet exporter to UAE
  • Dasatinib 50 mg exporter from India to USA
  • Dasatinib 50 mg supplier from India to UK
  • Dasatinib 50 mg pharmaceutical exporter Australia
  • Dasatinib 50 mg supplier Canada
  • Dasatinib 50 mg exporter Singapore
  • Dasatinib 50 mg supplier South Korea
  • Dasatinib 50 mg exporter UAE
  • oncology medicine exporter from Nagpur India
  • leukemia medicine supplier from India
  • anti cancer medicine exporter from India
  • prescription oncology medicine exporter India
  • pharmaceutical export company Nagpur India
  • Phoenix Exim medicine exporter Nagpur India
Aug 13th, 2026 3:18 PM

Keywords